CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
Abemaciclibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02919696
NCT02919696Phase 1Completed

A Phase 1 Study of Abemaciclib in Native Chinese Patients With Advanced and/or Metastatic Cancers

Eli Lilly and Company·interventional·Posted Sep 29, 2016·Updated Sep 25, 2020

In Brief

A Phase 1 clinical trial evaluating Abemaciclib for Advanced Cancer and Metastatic Cancer. Completed, enrolled 26 participants across 3 sites.

Detailed Summary

The purpose of this study is to determine the safety of the study drug known as abemaciclib in native Chinese participants with advanced and/or metastatic cancers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedSep 29, 2016
Enrollment StartAug 7, 2017
Primary CompletionNov 23, 2018
Study CompletionSep 3, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.8 years ago

Interventions

Abemaciclibdrug

Administered orally